43 related articles for article (PubMed ID: 19631733)
1. Immuno-inflammatory
Roser LA; Luckhardt S; Ziegler N; Thomas D; Wagner PV; Damm G; Scheffschick A; Hewitt P; Parnham MJ; Schiffmann S
Front Immunol; 2023; 14():1275368. PubMed ID: 38045689
[TBL] [Abstract][Full Text] [Related]
2. A proposed in vitro cytotoxicity test battery to detect and predict hepatotoxicity via multiple mechanisms and pathways: a minireview.
Sahu SC
J Appl Toxicol; 2024 Apr; ():. PubMed ID: 38686668
[TBL] [Abstract][Full Text] [Related]
3. Assessing immune hepatotoxicity of troglitazone with a versatile liver-immune-microphysiological-system.
Deng Q; Yang Y; Liu Y; Zou M; Huang G; Yang S; Li L; Qu Y; Luo Y; Zhang X
Front Pharmacol; 2024; 15():1335836. PubMed ID: 38873410
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.
Godoy P; Hewitt NJ; Albrecht U; Andersen ME; Ansari N; Bhattacharya S; Bode JG; Bolleyn J; Borner C; Böttger J; Braeuning A; Budinsky RA; Burkhardt B; Cameron NR; Camussi G; Cho CS; Choi YJ; Craig Rowlands J; Dahmen U; Damm G; Dirsch O; Donato MT; Dong J; Dooley S; Drasdo D; Eakins R; Ferreira KS; Fonsato V; Fraczek J; Gebhardt R; Gibson A; Glanemann M; Goldring CE; Gómez-Lechón MJ; Groothuis GM; Gustavsson L; Guyot C; Hallifax D; Hammad S; Hayward A; Häussinger D; Hellerbrand C; Hewitt P; Hoehme S; Holzhütter HG; Houston JB; Hrach J; Ito K; Jaeschke H; Keitel V; Kelm JM; Kevin Park B; Kordes C; Kullak-Ublick GA; LeCluyse EL; Lu P; Luebke-Wheeler J; Lutz A; Maltman DJ; Matz-Soja M; McMullen P; Merfort I; Messner S; Meyer C; Mwinyi J; Naisbitt DJ; Nussler AK; Olinga P; Pampaloni F; Pi J; Pluta L; Przyborski SA; Ramachandran A; Rogiers V; Rowe C; Schelcher C; Schmich K; Schwarz M; Singh B; Stelzer EH; Stieger B; Stöber R; Sugiyama Y; Tetta C; Thasler WE; Vanhaecke T; Vinken M; Weiss TS; Widera A; Woods CG; Xu JJ; Yarborough KM; Hengstler JG
Arch Toxicol; 2013 Aug; 87(8):1315-530. PubMed ID: 23974980
[TBL] [Abstract][Full Text] [Related]
5. Mechanistic Understanding of Idiosyncratic Drug-Induced Hepatotoxicity Using Co-Cultures of Hepatocytes and Macrophages.
Villanueva-Badenas E; Donato MT; Tolosa L
Antioxidants (Basel); 2023 Jun; 12(7):. PubMed ID: 37507855
[TBL] [Abstract][Full Text] [Related]
6. Microphysiological Models for Mechanistic-Based Prediction of Idiosyncratic DILI.
Stern S; Wang H; Sadrieh N
Cells; 2023 May; 12(11):. PubMed ID: 37296597
[TBL] [Abstract][Full Text] [Related]
7. Three-dimensional (3D) liver cell models - a tool for bridging the gap between animal studies and clinical trials when screening liver accumulation and toxicity of nanobiomaterials.
Tutty MA; Movia D; Prina-Mello A
Drug Deliv Transl Res; 2022 Sep; 12(9):2048-2074. PubMed ID: 35507131
[TBL] [Abstract][Full Text] [Related]
8. Recent Advances in Models of Immune-Mediated Drug-Induced Liver Injury.
Tasnim F; Huang X; Lee CZW; Ginhoux F; Yu H
Front Toxicol; 2021; 3():605392. PubMed ID: 35295156
[TBL] [Abstract][Full Text] [Related]
9. Study of the l-Phenylalanine Ammonia-Lyase Penetration Kinetics and the Efficacy of Phenylalanine Catabolism Correction Using In Vitro Model Systems.
Dyshlyuk L; Sukhikh S; Noskova S; Ivanova S; Prosekov A; Babich O
Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33805682
[TBL] [Abstract][Full Text] [Related]
10. Performance of preclinical models in predicting drug-induced liver injury in humans: a systematic review.
Dirven H; Vist GE; Bandhakavi S; Mehta J; Fitch SE; Pound P; Ram R; Kincaid B; Leenaars CHC; Chen M; Wright RA; Tsaioun K
Sci Rep; 2021 Mar; 11(1):6403. PubMed ID: 33737635
[TBL] [Abstract][Full Text] [Related]
11. Differential Monocyte Actuation in a Three-Organ Functional Innate Immune System-on-a-Chip.
Sasserath T; Rumsey JW; McAleer CW; Bridges LR; Long CJ; Elbrecht D; Schuler F; Roth A; Bertinetti-LaPatki C; Shuler ML; Hickman JJ
Adv Sci (Weinh); 2020 Jul; 7(13):2000323. PubMed ID: 32670763
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a human in vitro hepatocyte-NPC co-culture model for the prediction of idiosyncratic drug-induced liver injury: A pilot study.
Granitzny A; Knebel J; Müller M; Braun A; Steinberg P; Dasenbrock C; Hansen T
Toxicol Rep; 2017; 4():89-103. PubMed ID: 28959630
[TBL] [Abstract][Full Text] [Related]
13. From the Cover: Three-Dimensional (3D) HepaRG Spheroid Model With Physiologically Relevant Xenobiotic Metabolism Competence and Hepatocyte Functionality for Liver Toxicity Screening.
Ramaiahgari SC; Waidyanatha S; Dixon D; DeVito MJ; Paules RS; Ferguson SS
Toxicol Sci; 2017 Sep; 159(1):124-136. PubMed ID: 28633424
[TBL] [Abstract][Full Text] [Related]
14. Organotypic liver culture models: meeting current challenges in toxicity testing.
LeCluyse EL; Witek RP; Andersen ME; Powers MJ
Crit Rev Toxicol; 2012 Jul; 42(6):501-48. PubMed ID: 22582993
[TBL] [Abstract][Full Text] [Related]
15. Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver.
Rogue A; Spire C; Brun M; Claude N; Guillouzo A
PPAR Res; 2010; 2010():325183. PubMed ID: 20981297
[TBL] [Abstract][Full Text] [Related]
16. Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model.
Edling Y; Sivertsson LK; Butura A; Ingelman-Sundberg M; Ek M
Toxicol In Vitro; 2009 Oct; 23(7):1387-95. PubMed ID: 19631733
[TBL] [Abstract][Full Text] [Related]
17. Pro-inflammatory properties for thiazolidinediones.
Desmet C; Warzée B; Gosset P; Mélotte D; Rongvaux A; Gillet L; Fiévez L; Seumois G; Vanderplasschen A; Staels B; Lekeux P; Bureau F
Biochem Pharmacol; 2005 Jan; 69(2):255-65. PubMed ID: 15627478
[TBL] [Abstract][Full Text] [Related]
18. Gene expression analysis of troglitazone reveals its impact on multiple pathways in cell culture: a case for in vitro platforms combined with gene expression analysis for early (idiosyncratic) toxicity screening.
Vansant G; Pezzoli P; Saiz R; Birch A; Duffy C; Ferre F; Monforte J
Int J Toxicol; 2006; 25(2):85-94. PubMed ID: 16597547
[TBL] [Abstract][Full Text] [Related]
19. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
